Cargando…

DECAAF: Emphasizing the importance of MRI in AF ablation

Atrial fibrillation ablation is a complex and challenging procedure. Appropriate patient selection is the most critical step to ensure safe and successful atrial fibrillation ablation procedure. The DECAAF study (Delayed-Enhancement MRI Determinant of Successful Radiofrequency Catheter Ablation of A...

Descripción completa

Detalles Bibliográficos
Autores principales:	ElMaghawry, Mohamed, Romeih, Soha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bloomsbury Qatar Foundation Journals. 2015
Materias:	Lessons from the Trials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4374095/ https://www.ncbi.nlm.nih.gov/pubmed/25830152 http://dx.doi.org/10.5339/gcsp.2015.8

Ejemplares similares

ROCKET AF adds more concerns about Digoxin safety in patients with atrial fibrillation
por: ElMaghawry, Mohamed
Publicado: (2015)

FIRE AND ICE: The quest for the perfect modality in atrial fibrillation ablation
por: Sayed, Mohamed, et al.
Publicado: (2016)

Dronedarone-digoxin interaction in PALLAS: A foxglove connection?
por: ElMaghawry, Mohamed, et al.
Publicado: (2015)

Takotsubo cardiomyopathy: A potentially serious trap (Data from the International Takotsubo Cardiomyopathy Registry)
por: Wagdy, Kerolos, et al.
Publicado: (2015)

REVERSE 5-year follow up: CRT impact persists
por: ElMaghawry, Mohamed, et al.
Publicado: (2014)

STOP-HF: Expanding the role of HF programs into the community
por: ElMaghawry, Mohamed, et al.
Publicado: (2014)

BLOCK-HF: CRT gains new ground
por: ElGuindy, Ahmed M., et al.
Publicado: (2013)

ENGAGE AF: Effective anticoagulation with factor Xa in next generation treatment of atrial fibrillation
por: Kaba, Riyaz A, et al.
Publicado: (2013)

Catheter ablation improved ejection fraction in persistent AF patients: a DECAAF-II sub analysis
por: Mekhael, Mario, et al.
Publicado: (2023)

RAAFT-2: Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation
por: Kaba, Riyaz A, et al.
Publicado: (2014)

CTS Trials Network: Surgical ablation of atrial fibrillation during mitral valve surgery - many questions unanswered
por: Afifi, Ahmed
Publicado: (2015)

AMBITION: An important piece in the therapeutic puzzle of pulmonary arterial hypertension
por: Said, Karim
Publicado: (2015)

RENASICA II: A Mexican acute myocardial infarction registry that highlights the importance of regional registries
por: Al Suwaidi, Jassim
Publicado: (2014)

TASTE: One-year follow-up results
por: Elmahdy, Mahmoud Farouk, et al.
Publicado: (2015)

Gulf CARE: Heart failure in the Middle East
por: Hassan, Mohamed
Publicado: (2015)

STABILITY and SOLID-TIMI 52: Lipoprotein associated phospholipase A(2) (Lp-PLA(2)) as a biomarker or risk factor for cardiovascular diseases
por: Hassan, Mohamed
Publicado: (2015)

OSLER and ODYSSEY LONG TERM: PCSK9 inhibitors on the right track of reducing cardiovascular events
por: Hassan, Mohamed
Publicado: (2015)

HPS2-THRIVE, AIM-HIGH and dal-OUTCOMES: HDL-cholesterol under attack
por: Hassan, Mohamed
Publicado: (2014)

APOC3: Triglycerides do matter
por: Hassan, Mohamed
Publicado: (2014)

Niemann-Pick C1-Like 1 protein: Another target for treatment of dyslipidemia? Evidence from the Myocardial Infarction Genetic Consortium and IMPROVE-IT trials
por: Hassan, Mohamed
Publicado: (2014)

FOURIER & PCSK9 RNAi: Towards enhancing durability and efficacy of PCSK9 inhibitors
por: Hassan, Mohamed
Publicado: (2017)

CANTOS: A breakthrough that proves the inflammatory hypothesis of atherosclerosis
por: Hassan, Mohamed
Publicado: (2018)

Towards tailoring blood pressure control in HFpEF: Lessons from OPTIMIZE-HF
por: Hassan, Mohamed
Publicado: (2019)

PARTNER 2A & SAPIEN 3: TAVI for intermediate risk patients
por: ElGuindy, Ahmed
Publicado: (2016)

GAUSS-2, RUTHERFORD-2, LAPLACE-2, DESCARTES, and TESLA Part B: PCSK9 inhibitors gain momentum
por: Hassan, Mohamed, et al.
Publicado: (2014)

CANHEART: Is HDL cholesterol a cardiovascular specific risk factor?
por: Hassan, Mohamed, et al.
Publicado: (2016)

NEAT HFpEF: Organic nitrates fail to deliver
por: Wagdy, Kerolos, et al.
Publicado: (2016)

ASGR1 - a new target for lowering non-HDL cholesterol
por: Hassan, Mohamed, et al.
Publicado: (2016)

STREAM at one year: Further evidence supporting a pharmacoinvasive strategy in patients with STEMI
por: ElGuindy, Ahmed M.
Publicado: (2015)

FAME 2: Reshaping the approach to patients with stable coronary artery disease
por: ElGuindy, Ahmed M.
Publicado: (2015)

HEAT-PPCI: A clear and welcome win for heparin
por: ElGuindy, Ahmed M.
Publicado: (2014)

ALDO-DHF & Paramount
por: ElGuindy, Ahmed M
Publicado: (2013)

TOPCAT misses its primary endpoint: Should spironolactone be abandoned in HFpEF?
por: ElGuindy, Ahmed M.
Publicado: (2013)

STREAM and FAST-MI – Pharmacoinvasive therapy: A continued role for fibrinolysis in the primary PCI era
por: ElGuindy, Ahmed M.
Publicado: (2014)

The RIME trial: Are we closer to the answer of when to repair ischemic mitral regurgitation?
por: Afifi, Ahmed, et al.
Publicado: (2013)

PLATFORM at 90 days: Evaluating the clinical utility of FFRCT
por: Kharabish, Ahmed, et al.
Publicado: (2016)

The Prospective Randomized On-X Valve Anticoagulation Clinical Trial (PROACT): Lower is better, but is it good enough?
por: Bouhout, Ismail, et al.
Publicado: (2019)

PCI versus CABG in patients with complex coronary artery disease: Time for reconciliation?
por: ElGuindy, Ahmed M, et al.
Publicado: (2013)

Culprit lesion-only versus complete revascularization in patients with STEMI: Lessons learned from PRAMI, CvLPRIT, and DANAMI-3 PRIMULTI
por: Hassan, Ahmed, et al.
Publicado: (2015)

FAME 2 – The best initial strategy for patients with stable coronary artery disease: Do we have an answer at last?
por: ElGuindy, Ahmed M, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_r4bgdftnfq71ntlat7eaet7l8s